OBJECTIVE: To establish medicine use evaluation（MUE） criteria for cefoperazone and sulbactam

and to evaluate the application

so as to provide basis for clinical rational drug use. METHODS: Taking the drug instructions of cefoperazone and sulbactam as the criteria

referring to relevant literature and guidelines

the MUE criteria of cefoperazone and sulbactam was formulated by the expert consultation method. Retrospective analysis and simple random sampling were used to select 200 hospitalized children receiving cefoperazone and sulbactam in this hospital in 2019 and from Jul. to Dec. 2020 respectively

and the rationality of drug use was comprehensively evaluated. RESULTS: Based on the established MUE criteria

among 400 children in 2019 and from Jul. to Dec. 2020

the overall indication compliance rate was 92.2%（369 cases）（with expected target value of 90%）

the microbial inspection rate was 87.0%（348 cases）（with expected target value of 50%）

the rate of drug dosage and medication interval meeting the criteria was 78.0%（312 cases）（with expected target value of 90%）

the rate of solvent selection

route of administration

contraindications and prescription authority management meeting the criteria was 100%（400 cases）（with expected target value of 100%）

drug interactions meeting the criteria was 94.0%（376 cases）（with expected target value of 100%）

treatment course meeting the criteria was 88.5%（354 cases）（with expected target value of 95%）

and rational drug combination was 83.6%（73 cases of combined medication

of which 61 cases were reasonable）（with expected target value of 90%）. CONCLUSIONS: The established MUE criteria for cefoperazone and sulbactam in children can be used to evaluate the use of cefoperazone and sulbactam in clinical practice

regulate the rational use of medication by clinicians and improve the efficacy in children.